All In Biotech

Drug Trial Radar · NCT04678648

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Mar 3, 2021

Primary completion

Mar 16, 2027

Study completion Mar 17, 2028

Sponsor

Lead sponsor
RasCal Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Conditions

  • Advanced Malignant Solid Neoplasm
  • RAS Mutation
  • Lung Cancer
  • Colon Cancer
  • Glioblastoma
  • Pancreatic Cancer

Interventions

  • RSC-1255 Dose EscalationDrug

    Phase 1a will enroll 40-80 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, with and without food. Each cycle is 21 days.

  • RSC-1255 Dose ExpansionDrug

    Phase 1b will enroll 48-94 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily alone or in combination with continuous hydroxychloroquine, with food. Each cycle is 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapyTime frame: Approximately 30 months
  2. Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapyTime frame: Approximately 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology

    Los Angeles, California · Recruiting

  • Sarah Cannon, SCRI Oncology Partners - Health One

    Denver, Colorado · Recruiting

  • Sarah Cannon, SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.